Analysts Set Alphatec Holdings, Inc. (NASDAQ:ATEC) Target Price at $17.11

Alphatec Holdings, Inc. (NASDAQ:ATEC) has received an average rating of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $17.11.

Several equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Thursday, October 31st. Needham & Company LLC restated a “buy” rating and set a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st. Finally, Barclays upped their target price on shares of Alphatec from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Tuesday, November 19th.

Alphatec Trading Up 3.4 %

NASDAQ:ATEC opened at $9.37 on Friday. The business has a fifty day moving average price of $9.13 and a 200-day moving average price of $8.03. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -7.32 and a beta of 1.38. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec has a one year low of $4.88 and a one year high of $17.34.

Institutional Trading of Alphatec

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in Alphatec in the 3rd quarter worth about $69,000. Net Worth Advisory Group purchased a new position in shares of Alphatec during the third quarter worth approximately $76,000. Van ECK Associates Corp raised its stake in shares of Alphatec by 57.0% during the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after acquiring an additional 6,998 shares in the last quarter. Tempus Wealth Planning LLC purchased a new stake in shares of Alphatec in the third quarter valued at approximately $107,000. Finally, Atria Investments Inc grew its stake in Alphatec by 8.0% in the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after purchasing an additional 1,460 shares in the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.